Press release June 10, 2009 LinkMed's new share issue heavily oversubscribed Calculation of the outcome of the new share issue implemented by LinkMed shows that the issue was oversubscribed by 41 percent, which means that the guarantee commitments entered into need not be utilized. As a result of the new share issue, LinkMed will receive approximately SEK 91.3 million, before issue expenses. Of the new share issue, 98.5 percent, corresponding to 7,192,444 shares, were subscribed for on the basis of subscription rights. Applications to subscribe for shares without the support of subscription rights were made for approximately 42.7 percent of the issue, equivalent to 3,118,527 shares. New shares subscribed for without the support of subscription rights were allotted to shareholders who had subscribed for shares on the basis of subscription rights, in accordance with the principles stated in the prospectus published on May 12, 2009. A statement will be sent on or around June 10, 2009 confirming allotment of new shares to those subscribers who subscribed for new shares without the support of subscription rights. “Naturally, we are very pleased that such great interest was shown in LinkMed. The new share issue will give us the opportunity to create a well-positioned and profitable transplantation sector company by combining AbSorber and Olerup, in which the first steps may be a joint sales organization and the coordination of the resources of the two companies. We also now have the opportunity to continue to support the development of BioResonator, Biovator, Likvor and Ortoviva, all of which are at very interesting stages, with products close to market launch,” said Ingemar Lagerlöf, CEO LinkMed. As a result of the new share issue, the number of LinkMed shares will increase by 7,300,873 to 16,061,921 shares. Share capital will increase by SEK 7,300,873 to SEK 16,061,921. Paid subscription shares (”BTAs”) will be traded on NASDAQ OMX Stockholm until partial registration of the new shares with the Swedish Companies Registration Office has been effected. Only first class BTAs will be traded on NASDAQ OMX Stockholm. New shares subscribed to on the basis of subscription rights are expected to become subject to trading on NASDAQ OMX Stockholm on June 17, 2009. Shares subscribed to without preferential rights are expected to become subject to trading at the beginning of July 2009. Changes among the company's principal shareholders have occurred in conjunction with the new share issue. An updated list of the 15 largest shareholders will be published on LinkMed's website upon completion of the issue. Financial and legal advisors Swedbank Markets is LinkMed's financial advisor and Advokatfirman Lindahl is the company's legal advisor. For more information please contact: Ingemar Lagerlöf, CEO: +46 8 508 939 93 Okee Williams, Portfolio Manager +46 8 508 939 40 Visit LinkMed's website: www.linkmed.se IMPORTANT INFORMATION The information in this press release is not intended for distribution, publication or disclosure, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, Japan or New Zealand. The information in this press release shall not be regarded as an offer to sell shares or a request to acquire shares. Nor will any sale of the securities referred to herein be permissible in any jurisdiction where such an offer, request or sale would not be lawful without registration or applicable exemption from registration pursuant to the securities legislation of such a jurisdiction. A prospectus concerning the rights issue presented in this press release and the subsequent listing of new shares on NASDAQ OMX Stockholm has been prepared and has been approved and registered by the Swedish Financial Supervisory Authority. The information in this press release does not constitute an offering of LinkMed securities in the U.S.; nor will the securities be offered or sold in the absence of registration or exemption from registration pursuant to the American Securities Act of 1933, as well as the rules and regulations under this act. There is no intention of registering any part of an offering of LinkMed securities in the US or of implementing a public offering of shares in the US. The information in this press release may not be forwarded or distributed to any third party; nor may it be reproduced in any manner. It is not permissible to forward, distribute, reproduce or disclose this information, in full or in part. Failure to observe these directives could constitute a breach of the American Securities Act of 1933 or applicable laws in other jurisdictions. LinkMed develops life science companies in collaboration with innovators and other financiers. By contributing management expertise and capital, LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology. The company's principal shareholders are among others FastPartner, Koncentra Holding and the founder Ingemar Lagerlöf. LinkMed is listed on the NASDAQ OMX Nordic Exchange in the Small Cap section (ticker: LMED).
LinkMed's new share issue heavily oversubscribed
| Source: Allenex AB